Adjuvant chemotherapy and dose escalation in definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma

Hyeon Kang Koh, Younghee Park, Taeryool Koo, Hae Jin Park, Me Yeon Lee, Ah Ram Chang, Semie Hong, Hoonsik Bae

Research output: Contribution to journalArticle


Background/Aim: To validate the effect of treatment intensification on survival in esophageal squamous cell carcinoma (ESCC) patients undergoing definitive concurrent chemoradiotherapy (dCCRT). Patients and Methods: We reviewed the medical records of 73 ESCC patients who underwent dCCRT between 2006 and 2017 in 3 institutions. Results: The median follow-up time was 13.3 months. The median overall survival (OS) and locoregional recurrence-free survival (LRFS) were 13.3 and 11.2 months, respectively. The median radiotherapy dose was 55.8 Gy, and the median biologically effective dose (BED) was 65.8 Gy. Chemotherapy was given in all patients during dCCRT, and adjuvant chemotherapy was administered in 56 patients (76.7%). Adjuvant chemotherapy improved OS (3-year, 24.2% vs. 11.8%, p=0.004). Higher BED ≥70 Gy improved LRFS (3-year, 41.7% vs. 23.6%, p=0.035). Conclusion: The addition of chemotherapy after dCCRT improves OS. A higher radiotherapy dose improved LRFS, but not OS. Adjuvant chemotherapy should be considered after dCCRT for better outcomes.

Original languageEnglish
Pages (from-to)1771-1778
Number of pages8
JournalAnticancer Research
Issue number3
StatePublished - 2020 Jan 1



  • Adjuvant chemotherapy
  • Chemoradiotherapy
  • Esophageal squamous cell carcinoma
  • Radiotherapy dose escalation

Cite this